Phase 3 ECHO Trial: Study Design and Efficacy Data

February 21st 2025

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Tambiciclib plus zanubrutinib doubled the expected ORR of zanubrutinib monotherapy, eliciting an ORR of 67% in patients with relapsed or refractory DLBCL.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD

February 17th 2025

Study Finds Recent Falls, Inability to Balance on Left Leg Indicate OS Decrease in NHL

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Adverse physical functions were indicative of reduced survival and increased risk of ICANS in patients with non-Hodgkin lymphoma who were previously treated with CAR T-cell therapy.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Andrew M. Evens, DO, MBA, MSc

November 18th 2024

Age Did Not Negatively Impact Response From CAR T-Cell Therapy in R/R LBCL

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Ariana Pelosci

Venetoclax/Ibrutinib Significantly Improves PFS in Mantle Cell Lymphoma

Median PFS and OS were comparable between age groups when CAR T-cell therapy was given as treatment for patients with relapsed/refractory LBCL.

Roman Fabbricatore

Tambiciclib/Zanubrutinib Yields Promising Responses in R/R DLBCL

The safety profile of ibrutinib/venetoclax in the phase 3 SYMPATICO trial was consistent with the known profiles for each individual agent.

Related Content

February 21st 2025

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Tambiciclib plus zanubrutinib doubled the expected ORR of zanubrutinib monotherapy, eliciting an ORR of 67% in patients with relapsed or refractory DLBCL.

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD

February 17th 2025

Study Finds Recent Falls, Inability to Balance on Left Leg Indicate OS Decrease in NHL

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Adverse physical functions were indicative of reduced survival and increased risk of ICANS in patients with non-Hodgkin lymphoma who were previously treated with CAR T-cell therapy.

Andrew M. Evens, DO, MBA, MSc

November 18th 2024

Age Did Not Negatively Impact Response From CAR T-Cell Therapy in R/R LBCL

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Ariana Pelosci

Venetoclax/Ibrutinib Significantly Improves PFS in Mantle Cell Lymphoma

Median PFS and OS were comparable between age groups when CAR T-cell therapy was given as treatment for patients with relapsed/refractory LBCL.

Roman Fabbricatore